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Although transplant practices have changed over the last decades, no information is available on trends in
incidence and outcome of chronic graft-versus-host disease (cGVHD) over time. This study used the central
database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to describe time
trends for cGVHD incidence, nonrelapse mortality, and risk factors for cGVHD. The 12-year period was divided
into 3 intervals, 1995 to 1999, 2000 to 2003, and 2004 to 2007, and included 26,563 patients with acute
leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. Multivariate analysis showed an
increased incidence of cGVHD in more recent years (odds ratio ¼ 1.19, P < .0001), and this trend was still seen
when adjusting for donor type, graft type, or conditioning intensity. In patients with cGVHD, nonrelapse
mortality has decreased over time, but at 5 years there were no signiﬁcant differences among different time
periods. Risk factors for cGVHD were in line with previous studies. This is the ﬁrst comprehensive charac-
terization of the trends in cGVHD incidence and underscores the mounting need for addressing this major late
complication of transplantation in future research.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Chronic graft-versus-host disease (cGVHD) remains a
major complication after allogeneic hematopoietic cell
transplantation (HCT) and is the leading cause of nonrelapse
mortality (NRM) in patients surviving more than 2 years [1].
The incidence of cGVHD may be increasing despite the
advances in transplantation practices [2]. Several studies
have described risk factors associated with the potentially
increasing risk of cGVHD, such as transplantation from
donors other than matched sibling [3,4], the use of older
recipients [5,6], and the use of peripheral blood graft [7-9]. In
addition, better supportive care may have improved early
NRM such that more patients are at risk to develop cGVHD
and contribute to an increased incidence rate [10]. There is
also a recent report of a GVHD-induced graft-versus-leuke-
mia effect for myeloablative and reduced-intensity condi-
tioning (RIC) transplants [11]. Donor cell infusions (DCIs)
post-transplant have similarly contributed to cGVHD inci-
dence [12]. However, there have been no reports on the
trends in incidence and outcomes of cGVHD over time.The objective of this study was to evaluate the possible
differences in incidence and outcomes of cGVHD over crit-
ical time periods of practice change in allogeneic HCT,
spanning from 1995 to 2007. Three time periods were
chosen (1995 to 1999, 2000 to 2003, and 2004 to 2007) as
best estimates of intervals of practice change. This study
deﬁnes the time trends in cGVHD incidence, key clinical
characteristics, NRM, and overall survival (OS).METHODS
The data source for the study was the registry of the Center for Inter-
national Blood and Marrow Transplant Research (CIBMTR), the voluntary
working group of more than 500 transplantation centers that collaborates to
share patient data and conduct scientiﬁc studies. The quality and compli-
ance of data submission are monitored by computerized checks for errors,
physician reviews, and on-site audits.
Observational studies conducted by the CIBMTR are performed with
informed consent in accordance with the Declaration of Helsinki and in
compliance with Health Insurance Portability and Accountability Act regu-
lations as determined by the National Marrow Donor Program and Medical
College of Wisconsin institutional review boards.
Table 1
Characteristics of Patients Who Underwent Allogeneic Transplant for AML,
ALL, CML, and MDS by Time Period Reported to the CIBMTR from 1995 to
2007
Characteristics 1995-1999
n (%)
2000-2003
n (%)
2004-2007
n (%)
P
Number of patients 10,597 7472 8494
Number of centers 318 274 255
Median age, yr (range) 32 (<1-72) 35 (<1-79) 40 (<1-78) <.001
Age at transplant, yr <.001
0-9 1435 (14) 902 (12) 865 (10)
10-19 1637 (15) 1079 (14) 1129 (13)
20-29 1749 (17) 1151 (15) 1134 (13)
30-39 2407 (23) 1269 (17) 1154 (14)
40-49 2267 (21) 1420 (19) 1501 (18)
50-59 1026 (10) 1227 (16) 1729 (20)
60þ 76 (1) 424 (6) 982 (12)
Gender .51
Male 6071 (57) 4297 (58) 4812 (57)
Female 4526 (43) 3175 (42) 3682 (43)
Race <.001
White 8418 (79) 5743 (77) 6155 (72)
African American 435 (4) 313 (4) 408 (5)
Asian/Paciﬁc Islander 915 (9) 752 (10) 610 (7)
Hispanic 619 (6) 492 (7) 848 (10)
Native American 31 (<1) 20 (<1) 26 (<1)
Other 157 (1) 129 (2) 408 (5)
Unknown/missing 22 (<1) 23 (<1) 39 (<1)
Karnofsky score <.001
<80% 1013 (10) 711 (10) 664 (8)
80% 9478 (89) 6460 (86) 7410 (87)
Missing 106 (1) 301 (4) 420 (5)
Disease <.001
AML 3383 (32) 3139 (42) 4215 (50)
ALL 2662 (25) 1920 (26) 2174 (26)
CML 3670 (35) 1576 (21) 1095 (13)
MDS 882 (8) 837 (11) 1010 (12)
Disease status at
transplant*
<.001
Early 5452 (51) 3235 (43) 3959 (47)
Intermediate 2636 (25) 2066 (28) 2311 (27)
Advanced 2509 (24) 2171 (29) 2224 (26)
Conditioning regimen <.001
Myeloablative 10,409 (98) 6002 (80) 6234 (73)
Nonmyeloablative 188 (2) 1470 (20) 2260 (27)
Donorerecipient HLA
matchy
<.001
HLA-identical sibling 4880 (46) 2562 (34) 2339 (28)
Other relative 794 (7) 383 (5) 247 (3)
URD well matched 1265 (12) 2115 (28) 3453 (41)
URD partially matched 2127 (20) 1234 (17) 1379 (16)
URD mismatched 1259 (12) 620 (8) 319 (4)
UCB matched (6/6) 12 (<1) 27 (<1) 57 (1)
UCB 1 mismatched
(5/6)
47 (<1) 96 (1) 123 (1)
UCB 2 mismatch
(4/6)
213 (2) 435 (6) 577 (7)
Donor age, yr
HLA-identical sibling
0-9 446 (9) 182 (7) 112 (5)
10-19 720 (15) 312 (12) 297 (13)
20-29 858 (18) 376 (15) 346 (15)
30-39 1153 (24) 484 (19) 368 (16)
40-49 972 (20) 575 (22) 509 (22)
50-59 497 (10) 398 (16) 433 (19)
60þ 187 (4) 213 (8) 252 (11)
Missing 47 (1) 22 (1) 22 (1)
Other relative
0-9 50 (6) 19 (5) 12 (5)
10-19 102 (13) 31 (8) 26 (11)
20-29 138 (17) 68 (18) 41 (17)
30-39 193 (24) 98 (26) 59 (24)
40-49 159 (20) 92 (24) 50 (20)
50-59 89 (11) 42 (11) 38 (15)
60þ 55 (7) 30 (8) 20 (8)
Missing 8 (1) 3 (1) 1 (<1)
URD
18-19 20 (<1) 33 (1) 75 (1)
20-29 1196 (26) 1141 (29) 1614 (31)
30-39 1730 (37) 1463 (37) 1814 (35)
40-49 1166 (25) 965 (24) 1190 (23)
50-59 304 (7) 255 (6) 320 (6)
(Continued)
Table 1
(continued)
Characteristics 1995-1999
n (%)
2000-2003
n (%)
2004-2007
n (%)
P
60þ 200 (4) 95 (2) 111 (2)
Missing 35 (1) 17 (<1) 27 (1)
Donorerecipient sex
match
<.001
Femaleemale 2422 (23) 1639 (22) 1744 (21)
Others 8120 (77) 5823 (78) 6705 (79)
Missing 55 (1) 10 (<1) 45 (1)
Donorerecipient CMV
status
<.001
e/e 3313 (31) 2039 (27) 2294 (27)
Others 7161 (68) 5392 (72) 6116 (72)
Missing 123 (1) 41 (1) 84 (1)
Graft type <.001
Bone marrow 8479 (80) 3410 (46) 2383 (28)
Peripheral blood 1846 (17) 3504 (47) 5354 (63)
Cord blood 272 (3) 558 (7) 757 (9)
Developed cGVHD <.001
No 7387 (70) 5066 (68) 5403 (64)
Yes 3210 (30) 2406 (32) 3091 (36)
ATG and Campath usage
(received in
conditioning
regimen or GVHD
prophylaxis)
<.001
ATG and Campath 5 (<1) 1 (<1) 3 (<1)
ATG only 2114 (20) 2167 (29) 2350 (28)
Campath only 161 (2) 280 (4) 394 (5)
No ATG or Campath 8317 (78) 5024 (67) 5747 (68)
GVHD prophylaxis <.001
Ex vivo T cell depletion
alone
470 (4) 221 (3) 159 (2)
Ex vivo T cell
depletion þ post-
treatment immune
suppression
757 (7) 302 (4) 168 (2)
CD34 selection alone 39 (<1) 63 (1) 41 (<1)
CD34 selection þ post-
treatment immune
suppression
71 (1) 131 (2) 62 (1)
Cyclophosphamide
alone
0 0 17 (<1)
FK506 þ MMF  others 20 (<1) 254 (3) 894 (11)
FK506 þ MTX  others
(except MMF)
647 (6) 1279 (17) 2611 (31)
FK506 þ others (except
MTX, MMF)
167 (2) 120 (2) 220 (3)
FK506 alone 35 (<1) 117 (2) 189 (2)
CSA þ MMF  others
(except FK506)
36 (<1) 536 (7) 743 (9)
CSA þ MTX  others
(except FK506,
MMF)
7061 (67) 3471 (46) 2665 (31)
CSA þ others (except
FK506, MTX, MMF)
698 (7) 500 (7) 376 (4)
CSA alone 513 (5) 398 (5) 263 (3)
Other GVHD
prophylaxis
83 (1) 80 (1) 86 (1)
Prior acute GVHD grades <.001
0-II 7597 (72) 5388 (72) 6340 (75)
III-IV 2956 (28) 2068 (28) 2136 (25)
Missing 44 (<1) 16 (<1) 18 (<1)
URD indicates unrelated donor; UCB, unrelated cord blood; CMV, cyto-
megalovirus; ATG, antithymocyte globulin; FK506, tacrolimus; MMF,
mycophenolate mofetil; MTX, methotrexate; CSA, cyclosporine.
* Disease status is categorized as follows: Early ¼ AML/ALL (CR1 [ﬁrst
complete remission]); CML (CP1 [ﬁrst chronic phase]); MDS (RA/RARS [re-
fractory anemia/refractory anemia with ring sideroblasts]/pre-HCT marrow
blasts < 5%); Intermediate ¼ AML/ALL (CR2); CML (AP [accelerated phase]
or  CP2 [second chronic phase]); Advanced ¼ AML/ALL (REL [relapsed]/PIF
[primary induction failure]); CML in BP; MDS (RAEB [refractory anemia with
excess blasts]/RAEB-t [refractory anemia with excess blasts in trans-
formation]/chronic myelomonocytic leukemia or marrow blasts  5%).
y D-R HLA match: Well-matched URD cases had either no identiﬁed HLA
mismatch and informative data at 4 loci or allele matching at HLA-A, -B, and
-DRB1. Partially matched URD pairs had a deﬁned, single-locus mismatch
and/or missing HLA data. Mismatched URD cases had 2 allele or antigen
mismatches [32].
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Table 2
cGVHD Characteristics
Characteristics 1995-1999
n (%)
2000-2003
n (%)
2004-2007
n (%)
P
For patients who developed
cGVHD post-transplant
(patients were censored
at second transplant, DCI,
or relapse)
Time from transplant to
cGVHD onset, mo
(median, 5 mo)
.08
<5 1645 (51) 1267 (53) 1534 (50)
5 1565 (49) 1139 (47) 1557 (50)
Type of cGVHD onset <.001
Progressive 1408 (44) 854 (35) 855 (28)
Quiescent/interrupted 626 (20) 758 (32) 1171 (38)
De novo 834 (26) 687 (29) 1011 (33)
Missing/not collected
on prior forms
342 (11) 107 (4) 54 (2)
Maximum grade of cGVHD <.001
Limited 1175 (37) 677 (28) 856 (28)
Extensive 2019 (63) 1718 (71) 2227 (72)
Unknown/missing 16 (<1) 11 (<1) 8 (<1)
Maximum overall
severity of cGVHD
<.001
Mild 1085 (34) 955 (40) 1297 (42)
Moderate 852 (27) 817 (34) 1102 (36)
Severe 466 (15) 470 (20) 641 (21)
Unknown/missing 807 (25) 164 (7) 51 (2)
Number of cGVHD organ
involved at maximum
severity
<.001
1 675 (21) 534 (22) 837 (27)
2 677 (21) 478 (20) 708 (23)
3 560 (17) 389 (16) 537 (17)
4 411 (13) 330 (14) 371 (12)
5þ 604 (19) 528 (22) 429 (14)
Missing 283 (9) 147 (6) 209 (7)
Systemic
immunosuppression
given
<.001
Yes 2697 (84) 2253 (94) 2979 (96)
No 428 (13) 133 (6) 100 (3)
Missing 85 (3) 20 (1) 12 (<1)
cGVHD organ involved
at maximum severity
Skin  other 1650 (51) 1563 (65) 2192 (71)
Eyes  other 1145 (36) 811 (34) 657 (21)
Mouth  other 1384 (43) 1149 (48) 980 (32)
Lung  other 456 (14) 398 (17) 522 (17)
GI/weight loss  other 1261 (39) 995 (41) 1050 (34)
Liver  other 1525 (48) 1178 (49) 1399 (45)
Other organ
involvement  other
1163 (36) 798 (33) 985 (32)
Median follow-up,
mo (range)
113 (3-196) 82 (3-135) 49 (3-89)
DCI-associated cGVHD
Total number patients
with cGVHD after DCI
77 68 73
Mild 19 27 29
Moderate 22 26 28
Severe 16 13 14
GI indicates gastrointestinal.
Figure 1. In the multivariate analysis, higher risk of cGVHD in the most recent
time period (2004-2007 versus 1995-1999: OR ¼ 1.19, P < .0001; and 2004-
2007 versus 2000-2003: OR ¼ 1.13, P ¼ .002).
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Adult and pediatric patients reported to the CIBMTR with acute
myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic
myeloid leukemia (CML), and myelodysplastic syndrome (MDS) who had
their ﬁrst allogeneic transplant between 1995 and 2007 were included in
the study. Recipients of all graft sources, donor types, and conditioning
intensity were included.
Study Deﬁnitions
For this study, incidence was deﬁned as the development of cGVHD
within 1 year after transplant. The event was summarized by the cumulative
incidence estimate. In analysis, death, second transplant, DCI, and relapse
were considered competing risks.
NRMwas deﬁned as death in continuous complete remission. The event
was summarized by the cumulative incidence estimate with relapse as the
competing risk. OS was deﬁned as death from any cause. Nonmyeloablative
conditioning or RIC regimens were deﬁned as busulfan dose <9 mg/kg,melphalan dose <150 mg/m2, and total body irradiation dose 500 cGy
(single or fractionated) or 500 to 800 cGy (fractionated).
cGVHD was diagnosed according to Seattle criteria [13]. The new Na-
tional Institutes of Health (NIH) consensus criteria had not yet been
implemented on CIBMTR forms for this analysis [14]. The CIBMTR deﬁnition
of mild, moderate, and severe categories of cGVHD was used as described
before [15]. The CIBMTR deﬁnitions of cGVHD onset (progressive, quiescent,
de novo) were used [2].
Statistical Analysis
The main objective of this study was to look at the cumulative incidence
of any cGVHD (limited or extensive) as a time trend in transplants performed
from 1995 to 2007. The main variable, year of transplant, was treated either
as a categorical variable with groups 1995 to 1999, 2000 to 2003, 2004 to
2007 or as a continuous variable for testing the trend when a linear trend
was reasonable. Descriptive analysis was performed to analyze maximum
severity of the cGVHD within 1 year using chi-square tests. Descriptive
analyses were performed to deﬁne cGVHD subsets (mild, moderate, severe
or progressive, quiescent, de novo) and major organ and number of organ
involvement (eye, mouth, skin, liver, lung, gastrointestinal).
Among all patients who developed cGVHD, 91.3% of patients developed
cGVHD within 1 year after transplant. The remaining 8.7% of patients
developing cGVHD after 1 year were censored and were not included in the
analyses as having cGVHD.
The cumulative incidence estimator was used to calculate the proba-
bilities of cGVHD [16]. The overall mortality trend was evaluated using the
log-rank test and Kaplan-Meier estimator [17]. We also looked at NRM and
OS only in patients who had cGVHD by left truncation from the time of
diagnosis of cGVHD. Multivariate analysis on the cumulative incidence of
cGVHD at 1 year after transplantationwas performedwith the pseudo-value
approach [18] by using 2 methodologies: either treating only death as a
competing risk or treating death, second transplant, DCI, and relapse as
competing risks. Both demonstrated similar results; hence, the results from
the second method (treating death, second transplant, DCI, and relapse as
competing risks) are reported.
A stepwise model selection procedure was used to determine clinical
variables affecting the incidence of cGVHD. The multivariate analysis eval-
uated the categorical year of transplant as the main variable and also
assessed the possible interactions of the adjusted clinical variables with the
year of transplant. To adjust for multiple testing, P < .01 was considered
statistically signiﬁcant for themain outcome variable of interest. SAS version
9.2 (SAS Institute, Cary, NC) was used for all analyses.
RESULTS
Patient Characteristics
Baseline characteristics are shown in Table 1. The study
population included all patients (N ¼ 26,563) who
Figure 2. Increased cGVHD incidence when stratiﬁed by (A) donor type (HLA identical sibling: HR ¼ 1.17; unrelated donor: HR ¼ 1.07; cord blood: HR ¼ 1.24, all
P < .01), (B) graft type (PBSC: HR ¼ 1.19; cord blood: HR ¼ 1.24, P < .01), or (C) conditioning intensity (myeloablative: HR ¼ 1.13; reduced intensity: HR ¼ 1.16, P < .01).
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n ¼ 10,737; ALL, n ¼ 6756), CML (n ¼ 6341), and MDS
(n ¼ 2729) from 1995 to 2007. There were 10,597 patients
transplanted between 1995 and 1999, 7472 patients trans-
planted between 2000 and 2003, and 8494 patientstransplanted between 2004 and 2007. Over the course of
time, transplantation for AML became more frequent, age at
transplantation increased, and the use of nonmyeloablative
conditioning/RIC, alternative donors, and peripheral blood
stem cell (PBSC) grafts all increased.
Table 3
Univariate Analysis of NRM and OS of all Patients
Outcome
Events
No. of Patients
at Risk
1995-1999
Prob (95% CI)
No. of Patients
at Risk
2000-2003
Prob (95% CI)
No. of Patients
at Risk
2004-2007
Prob (95% CI)
P
NRM
At 100 d 7334 21 (21-22) 5127 17 (16-18) 6255 11 (11-12) <.001
At 1 yr 4908 32 (31-33) 3258 28 (27-29) 3947 21 (21-22) <.001
At 3 yr 3742 36 (35-37) 2337 32 (31-33) 2430 26 (25-27) <.001
At 5 yr 3114 37 (36-38) 1714 33 (32-34) 977 29 (28-30) <.001
OS
At 1 yr 5555 54 (53-55) 3842 53 (52-54) 4494 59 (58-60) <.001
At 3 yr 4264 44 (43-45) 2744 42 (40-43) 2723 44 (43-46) <.001
At 5 yr 3558 41 (40-42) 1993 38 (37-39) 1101 39 (38-40) .002
Prob indicates probability; CI, conﬁdence interval.
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cGVHD characteristics are shown in Table 2. Both uni-
variate and multivariate analyses showed a signiﬁcantly
increased incidence of cGVHD in recent time periods. In
univariate analysis, the cGVHD rates at 1 year by time period
were 28% for 1995 to 1999, 31% for 2000 to 2003, and 37% for
2004 to 2007 (P < .001). In the multivariate analysis
(Figure 1), the most recent time period (2004 to 2007) was
associated with higher risk of cGVHD when compared with
the 2 earlier time periods (2004 to 2007 versus 1995 to 1999:
odds ratio [OR] ¼ 1.19, P < .0001; and 2004 to 2007 versus
2000 to 2003: OR ¼ 1.13, P ¼ .002). This trend of increased
cGVHD incidence was noted when stratiﬁed by donor type
(HLA identical sibling: hazard ratio [HR] ¼ 1.17; unrelated
donor: HR ¼ 1.07; cord blood: HR ¼ 1.24; all P < .01;
Figure 2A), graft type (PBSC: HR ¼ 1.19; cord blood:
HR ¼ 1.24; P < .01; Figure 2B), or conditioning intensity
(myeloablative: HR¼ 1.13; RIC: HR¼ 1.16; P< .01; Figure 2C).
In mismatched related donors (HR ¼ 1.08, P ¼ .24) and bone
marrow graft type (HR ¼ 1.01, P ¼ .54), there was no signif-
icant change in the incidence of cGVHD over time. An anal-
ysis of cGVHD incidence over time stratiﬁed by disease (AML,
ALL, CML, MDS) showed a signiﬁcant increase in incidence
for all diseases except CML, which had no signiﬁcant change.Presenting Features of cGVHD
Progressive cGVHD (deﬁned as acute GVHD progressed
directly to cGVHD) [2] was found to be less frequently
diagnosed over time as compared with quiescent or de novo
cGVHD (Table 2). Because this trend might be from the
recognition of the late acute classiﬁcation in the 2005 NIH
cGVHD consensus criteria [14], we attempted to capture the
proportion of late acute GVHD patients within the group of
early progressive onset patients. To do the calculation, we
determined that 4756 patients developed cGVHD withinTable 4
Univariate Analysis of NRM and OS of Patients without cGVHD (Patients Who Develo
cGVHD)
Outcome
Events
No. of Patients
at Risk
1995-1999
Prob (95% CI)
No. of Patients
at Risk
NRM
At 100 d 6888 21 (21-22) 4821
At 1 yr 2737 29 (28-30) 1671
At 3 yr 1909 31 (30-32) 1071
At 5 yr 1572 31 (30-32) 735
OS
At 1 yr 3176 55 (54-56) 2016
At 3 yr 2184 46 (45-48) 1254
At 5 yr 1807 44 (43-45) 8545 months of transplant. Within this group, 1635 patients
were categorized as progressive onset cGVHD, and within
these 1635 patients, 937 (57%) were diagnosed between
100 days and 5 months of HCT. We further examined the
organ involvement of the 937 early progressive onset pa-
tients and determined that isolated skin, gut, or liver or
combinations of these, suggesting late acute GVHD, was
present in 628 patients. Thus, late acute GVHD might
comprise about 13% (628/4756) of the overall early cGVHD
patients. Although this numbermay not capture all late acute
patients, our data suggest this as a possibility in this cohort.
Overlap syndrome in the NIH criteria could also have been
included under progressive onset and accounted for some of
the decline in progressive onset reporting after 2005 [19].
Extensive, moderate, and severe categories of cGVHD
were more frequent in the 2 most recent time periods (2000
to 2003 and 2004 to 2007) as compared with the earliest
time period (1995 to 1999). Skin involvement at the
maximum severity was more frequent in recent years, the
greatest association with peripheral blood (33% in 2004 to
2007) compared with bone marrow (25% in 2004 to 2007,
P < .001, data not shown).NRM and OS Over Time
Univariate analyses of NRM and OS for all patients, pa-
tients without cGVHD, and patients with cGVHD are shown
in Tables 3-5, respectively. NRM for all transplanted patients
has decreased over time (Table 3). For patients without
cGVHD, the NRM at 1 and 3 years went from 29% and 31%,
respectively, in the 1995 to 1999 time period to 20% and 21%,
respectively, in the 2004 to 2007 time period (Table 4).
Similarly, for patients with cGVHD, the 1- and 3-year NRM
was lower in more recent years; however, the trend has not
continued in year 5, suggesting the risk of NRM persists over
time for those who continue to have active cGVHD (Table 5).ped cGVHDWere Included and Censored at the TimeWhen They Developed
2000-2003
Prob (95% CI)
No. of Patients
at Risk
2004-2007
Prob (95% CI)
P
17 (16-18) 5910 12 (11-12) <.001
25 (24-26) 1762 20 (19-21) <.001
26 (25-27) 896 21 (20-22) <.001
27 (26-28) 361 22 (21-23) <.001
54 (53-55) 2049 58 (57-59) <.001
44 (43-45) 1015 46 (45-48) .018
41 (40-43) 411 43 (41-45) .016
Table 5
Univariate Analysis of NRM and OS of Patients with cGVHD (Left Truncation)
Outcome
Events
No. of Patients
at Risk
1995-1999
Prob (95% CI)
No. of Patients
at Risk
2000-2003
Prob (95% CI)
No. of Patients
at Risk
2004-2007
Prob (95% CI)
P
NRM
At 1 yr 2170 27 (25-29) 1590 25 (22-28) 2178 18 (16-20) <.001
At 3 yr 1824 36 (34-39) 1266 36 (33-39) 1500 30 (28-32) <.001
At 5 yr 1533 40 (38-42) 957 40 (37-42) 612 37 (34-39) .11
OS
At 1 yr 2379 67 (65-69) 1826 67 (65-70) 2446 73 (71-75) .0002
At 3 yr 2081 53 (51-55) 1490 51 (48-53) 1676 53 (51-55) .189
At 5 yr 1749 48 (46-50) 1129 46 (43-48) 690 45 (45-47) .078
Table 6
Multivariate Analysis of cGVHD at 1 Year after Transplant Treating Death,
Second Transplant, DCI, and Relapse as Competing Risks
Variables n OR (95% CI) P
Year of transplant .0001
1995-1999 10,444 1.00
2000-2003 6573 1.06 (.98, 1.14) .1646
2004-2007 6711 1.19 (1.1, 1.3) <.0001
Contrast comparison
2004-2007 vs. 2000-2003
1.13 (1.05, 1.22) .002
Age at transplant <.0001
0-9 yr 2965 1.00
10-19 yr 3596 1.22 (1.07, 1.39) 0.0029
20-29 yr 3769 1.57 (1.38, 1.78) <.0001
30-39 yr 4537 1.61 (1.41, 1.82) <.0001
40-49 yr 4732 1.6 (1.41, 1.82) <.0001
50-59 yr 3222 1.52 (1.32, 1.74) <.0001
60 yr 907 1.19 (.97, 1.46) .0999
ATG or Campath <.0001
Yes 17,160 1.00
No 6568 1.76 (1.63, 1.91) <.0001
Disease <.0001
AML 9200 1.00
ALL 6217 .98 (.9, 1.06) .6077
CML 6007 1.24 (1.15, 1.34) <.0001
MDS 2304 1.44 (1.3, 1.6) <.0001
Disease status at transplant <.0001
Early 11,433 1.00
Intermediate 6280 .88 (.82, .95) .0005
Advanced 6015 .54 (.5, .59) <.0001
Donor and graft type <.0001
BM, HLA-identical sibling 4611 1.00
BM, other relative 721 1.13 (.91, 1.4) .281
BM, URD well matched 3414 1.83 (1.65, 2.04) <.0001
BM, URD mismatched 1726 1.37 (1.19, 1.57) <.0001
PBSC, HLA-identical sibling 4573 1.67 (1.51, 1.84) <.0001
PBSC, other relative 655 1.53 (1.22, 1.9) .0002
PBSC, URD well matched 2288 2.56 (2.26, 2.9) <.0001
PBSC, URD partially matched 1018 2.75 (2.36, 3.21) <.0001
PBSC, URD mismatched 333 2.19 (1.71, 2.8) <.0001
5/6 UCB 204 1.16 (.73, 1.83) .5308
4 or less/6 UCB 932 1.2 (.96, 1.51) .1143
GVHD prophylaxis <.0001
CSA þ MTX  others
(except FK506, MMF)
13,178 1.00
Ex vivo T cell depletion 2483 .53 (.46, .6) <.0001
CSA  others 2698 1.03 (.92, 1.15) .6191
FK506 þ MTX  others
(except MMF)
4528 1.05 (.97, 1.14) .1979
FK506  others 841 1.01 (.87, 1.19) .8693
Performance score <.0001
<80% 2099 1.00
80% 20,919 1.44 (1.28, 1.62) <.0001
Unknown 710 1.39 (1.14, 1.68) .001
Conditioning regimen .0021
Myeloablative 21,264 1.00
Nonmyeloablative/RIC 2464 .84 (.76, .94) .0021
Donorerecipient sex match <.0001
Female donor, male recipient 5218 1.00
Other 18,424 .71 (.66, .76) <.0001
Unknown 86 .92 (.58, 1.43) .6996
BM indicates bone marrow.
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without cGVHD has not changed in recent time periods.
There were 15,781 deaths for the entire cohort. The major
cause of death for the entire patient cohort was relapse of the
primary disease (n ¼ 5263 [33%]), followed by infection
(n ¼ 2690 [17%]), organ failure (n ¼ 2064 [13%]), and GVHD
(n ¼ 2039 [13%]); this trend was consistent across all 3 time
periods. Death from disease relapse was 28% for the 1995 to
1999 time period (1827/6492), 34% for 2000 to 2003 (1577/
4627), and 40% for 2004 to 2007 (1859/4662) (Supplemental
Table 1). For patients who developed cGVHD, themajor cause
of death was also relapse of the primary disease. Thus, death
from late relapse still persists in cGVHD patients. Relapse rate
by severity grade of cGVHD was outside the focus of this
study; however, a previous International Bone Marrow
Transplant Registry/National Marrow Donor Program publi-
cation [15] has shown no association of relapse rate with
cGVHD severity (mild, moderate, severe).
Factors Affecting the Incidence of cGVHD
Results of the multivariate analysis are shown in Table 6.
The use of bone marrow with an unrelated donor (matched
or mismatched) and PBSC graft with all categories of donor
group was associated with higher risk of cGVHD, as
compared with the use of bone marrow with a matched
sibling donor. The risk of cGVHD was lower for unrelated
cord blood 5/6 or 4/6 mismatched compared with an un-
related PBSC graft (matched or mismatched) and was similar
to a bone marrow graft with a matched sibling donor. Ex-
pected associations of higher risk of cGVHD with female-to-
male transplants (P < .0001) and lower risk with T cell
depletion (OR ¼ .53, P < .0001) were also seen. Other com-
binations of GVHD prophylaxis did not affect the incidence of
cGVHD over the time periods. Cytomegalovirus status of the
donorerecipient pair also did not impact cGVHD incidence in
our model. The analysis did demonstrate a statistically sig-
niﬁcant decrease in cGVHD risk after nonmyeloablative/RIC
transplant (OR ¼ .84, P ¼ .0021).
DISCUSSION
In this large-scale analysis, we identify a clear increase in
the incidence of cGVHD over the study time period from
1995 to 2007. This trend was conﬁrmed despite controlling
for factors related to donor, graft, and conditioning regimen
associated with that trend. One possible explanation for this
unfavorable trend in cGVHD is the steadily increasing
number of long-term survivors because of lower early NRM
[20]. However, in the analysis focused only on patients who
survived beyond 100 days post-transplant, this trend was
maintained. Multiple factors are thus inﬂuencing the
increased cGVHD incidence trend besides long-term survi-
vorship. Our study conﬁrmed the increase over time in
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PBSC grafts, and use of alternative donors, all of which
associate with increased cGVHD and have been previously
described [21]. Moderate and severe categories of cGVHD
were more frequently observed in recent years, further
emphasizing the impact of more recent transplant strate-
gies on cGVHD severity. A trend in cGVHD onset type with
progressive less frequently diagnosed and quiescent or de
novo cGVHD more frequently diagnosed over time may
reﬂect more of a shift in deﬁnitions rather than an actual
increase in quiescent and de novo onsets. One might spec-
ulate that improved early NRM suggests decreased mor-
tality of acute GVHD and therefore more patients living to a
quiescent or de novo onset.
Clearly, NRM at 1 and 3 years has improved signiﬁcantly
over the observed time periods for patients both with and
without cGVHD. This trend is consistent with improvements
in supportive care introduced in allogeneic HCT over the
years [20]. The trend toward less severe (grades III to IV)
acute GVHD (Table 1) and fewer deaths from infection
(Supplemental Table 1) over time may have contributed to
the observed decrease in early NRM. Possibly the increased
use of PBSC grafts over time has impacted early NRM by
resulting in faster neutrophil engraftment and earlier re-
covery of immunity to fungal and bacterial infections [20].
Long-term OS over the 3 time periods, however, has not
signiﬁcantly improved. These OS results are not unlike other
reports on recent survival trends after allogeneic transplant
[21,22] where improvements in day 100 survival did not
translate into equally improved 1-year OS. This is because
relapse remains the major cause of death over time. In sup-
port of this ﬁnding is the increased cumulative incidence of
relapse for all patients on the study at years 3 and 5 over time
(Supplemental Table 2). The relapse trend persists even
when separating patients with and without cGVHD
(Supplemental Table 3). Although our study did not focus on
cGVHD impact on relapse, we can infer from the NRM and OS
outcomes in our analysis that early 1-year survival has
improved over time for cGVHD patients, perhaps from an
early protective effect of cGVHD against relapse, but 3- and 5-
year OS has not changed because of late relapses and from no
greater protection from cGVHD after 1 year, especially for
myeloablative transplants [11].
In the multivariate analysis, the identiﬁed risk factors for
increased cGVHD incidence were not unexpected. Increased
age at transplant [5,6], patients with CML and MDS [23,24],
use of unrelated donors, female donor into male recipient
[3,4] and use of PBSC grafts [7-9,25] are in accordance with
previous reports on risk factors for cGVHD incidence. The
reduced risk with antithymocyte globulin [26] or alemtu-
zumab [27] and ex vivo T cell depletion [28] is also in
accordance with previous studies. Information on lower risk
of cGVHD after nonmyeloablative conditioning and RIC
transplants observed in this current study enhances our
knowledge on this topic [29-31]. We recognize the limita-
tions of this study as historical data collection via registry
that did not include the recent NIH consensus criteria for
cGVHD classiﬁcation [13], which might impact some of the
trends seen. Still, this information is obtained on a very large
cohort of transplanted patients, and the characterization of
the recent trends in cGVHD is the best available data to date.
With cGVHD classiﬁcation currently undergoing reﬁned
deﬁnitions from the 2005 NIH consensus, it is of value to
comprehensively report our historical data because it may
serve as a basis for future comparison.In summary, these ﬁndings of cGVHD trends observed
over a 12-year period provide convincing evidence of
increasing cGVHD incidence in recent years and the factors
associated with these trends. We see that newer transplant
practices have also impacted early NRM in cGVHD patients
but that 5-year NRM and OS have not signiﬁcantly changed
over time, suggesting adverse impact of protracted immu-
nological derangements associated with cGVHD. These data
provide the compelling epidemiological background on the
current trends in cGVHD, which remains a major barrier for
successful allogeneic HCT. They serve also as a helpful
reference to guide future research efforts by the transplant
and hematology community.ACKNOWLEDGMENTS
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